Tag Archives: jak

Eighty percent of bowel cancers halted with existing medicines

The study found that medicines called ‘JAK inhibitors’ halted tumour growth in bowel cancers with a genetic mutation that is present in more than 80 per cent of bowel cancers. Multiple JAK inhibitors are currently used, or are in clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood cancers and myeloproliferative disorders. Bowel cancer is the second-most common cancer in Australia with nearly 17,000 people diagnosed every year, accounting for almost one out of 10 cancer-related deaths. Dr Toby Phesse, Dr Michael Buchert, Associate Professor Matthias Ernst and colleagues from Melbourne’s Walter and Eliza Hall Institute, in collaboration with Australian and international researchers, commenced the study while at the Melbourne-Parkville branch of the Ludwig Institute for Cancer Research…

Some aggressive cancers may respond to anti-inflammatory drugs — ScienceDaily

source : http://www.sciencedaily.com/releases/2014/06/140627145932.htm

Development of a novel dual JAK/Src kinase inhibitor

The research article by Liu et al describes MLS-2384 which is a synthetic derivative of amarine natural product, 6-bromoindirubin-3′-oxime. MLS-2384 exhibits a dual JAK/Src kinase inhibitory activity, blocks downstream signaling into the STAT3 pathway, and has anti-cancer activity in various human cancer cell lines. These findings have important clinical implications for understanding the mechanisms of action of bromoindirubin derivatives. The findings also indicate that this new 6-bromoindirubin derivative, MLS-2384, has potential as an anti-tumor therapeutic agent targeting JAK and Src kinases upstream of STAT3 in a wide variety of human cancer cells…